Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederesmo.org
ESMO News
Get the latest updates from ESMO News directly as they happen.
Follow now 76 followers
Latest posts
Last updated about 22 hours ago
Early-Stage and Locally Advanced NSCLC: ESMO Clinical Practice Guideline
about 22 hours ago
This updated ESMO CPG provides diagnosis, staging, risk assessment, treatment and follow-up...
Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide
about 23 hours ago
Findings from the ISG/OS-2 and GEIS-33 studies
Molecular Analysis for Precision Oncology Congress 2025, Paris, France, 15-16 September
2 days ago
The Molecular Analysis for Precision Oncology Congress 2025 (MAP) will bring together...
Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC
2 days ago
Findings from the PEACE-3 study
In Memory of Håkan Mellstedt: Former ESMO President
3 days ago
It is with deep sadness that ESMO has learnt of the passing...
EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel
3 days ago
It is intended for the treatment of adults from 26 years of...
Additional 5 Years of AI Treatment Reduces Distant Recurrence Rates Among Postmenopausal Women Already Treated with at Least 5 Years of Endocrine Therapy
4 days ago
Findings from a meta-analysis performed by the Early Breast Cancer Trialists' Collaborative...
FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma
7 days ago
Evidence for efficacy is based on results from the ONC006, ONC013, ONC014...
Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib in Patients with Advanced Clear Cell RCC
8 days ago
Findings from the KEYNOTE-426 study
Adagrasib Improves PFS Over Docetaxel in Patients with Previously Treated KRASG12C-mutated NSCLC
9 days ago
Findings from the KRYSTAL-12 study
No Survival Benefit from Adding Adjuvant Chemotherapy to Endocrine Therapy in Older Women with a Genomic Grade Index High-Risk ER-positive, HER2-negative Breast Cancer
10 days ago
Findings from the ASTER 70s study
EMA Recommends Granting a Marketing Authorisation for Belantamab Mafodotin
11 days ago
It is intended for the treatment of patients with relapsed or refractory...